Wu Kun

Wukun Biotech is a synthetic biology company headquartered in Shanghai, China, specializing in the design and evolution of novel protein therapeutics. Founded by Dr. Kun Wu, an alumnus of the David Baker lab, the company utilizes an AI-driven platform to engineer enzymes with enhanced stability and activity for metabolic and oncological applications. Their lead programs focus on enzyme replacement therapies for conditions such as phenylketonuria and gout. Wukun Biotech aims to address unmet medical needs by creating "programmable" medicines through advanced computational protein design. The company has successfully raised significant venture capital from prominent investors like IDG Capital and Source Code Capital to advance its pipeline. By integrating high-throughput screening with computational modeling, Wukun Biotech is positioned as a leader in the next generation of protein engineering in Asia.